Merli G., Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin, given once or twice daily, is as effective and safe as intravenous unfractionated heparin for treating acute venous thromboembolic disease subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med.2001;134: 191-202.
2.
Walenga JM, Jeske WP, Prechel MM, et al. Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Semin Thromb Hemost.2004;(supp1):69-80.
3.
Warkentin TE , Levine MN, Hirsh J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin . N Engl J Med.1995;332:1330-1335.
4.
Hofmann T.Clinical application of enoxaparin. Expert Rev Cardiovasc Ther. 2004;2:321-337
5.
Noble S., Peters DH, Goa KLEnoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs . 1995;49:388-410.
